Public Policy Letters, Statements, Legal Briefs, & Other Responses
← Back to all Letters & Statements
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
Sign-on Letter Opposing Updated VALID Act & ACM Exemption
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft